Why Ipamorelin over GHRP-6 or GHRP-2?

Ipamorelin is the most selective GHSR agonist — it doesn't significantly raise cortisol or prolactin, which is desirable for most users. GHRP-6 causes hunger via ghrelin crosstalk; GHRP-2 raises prolactin noticeably.

Is the DAC version of CJC-1295 better than no-DAC?

They serve different purposes. DAC (long-acting) produces tonic, non-pulsatile GH elevation, which does not mimic physiology and can downregulate the feedback loop. No-DAC matches a single natural pulse and is preferred for pulsatile protocols.

Growth-Hormone Secretagogues

CJC-1295 + Ipamorelin

Name: CJC-1295 + Ipamorelin
Brand: Research-Grade
Availability: InStock

Research-Grade

The CJC-1295 + Ipamorelin pairing exemplifies the classic 'dual-pathway' approach to pulsatile growth-hormone (GH) release. CJC-1295 is a modified analog of growth-hormone-releasing hormone (GHRH): its DAC (Drug Affinity Complex) version covalently binds serum albumin for a half-life measured in days; the no-DAC form (sometimes called Modified GRF 1-29) acts for 20–30 minutes, matching a single endogenous GH pulse. Ipamorelin is a selective growth-hormone secretagogue (GHRP-class) that binds the ghrelin/GHSR receptor and — unlike earlier GHRPs such as GHRP-6 or GHRP-2 — shows minimal affinity for cortisol, prolactin, or aldosterone pathways. Combined, they produce a stronger and more physiological GH pulse than either alone: GHRH analogs open the somatotroph and GHS-R agonists amplify release. Typical preclinical and off-label protocols use daily or thrice-weekly subcutaneous injections timed to fasted periods (morning or pre-bed) to avoid competitive blunting from post-prandial insulin or carbohydrate intake. The pairing remains a research peptide; human clinical use is off-label and varies widely by jurisdiction.

Specifications

Dose Range	CJC-1295 (no-DAC) 2–5 mg/vial; Ipamorelin 2–5 mg/vial
Origin / Manufacturer	Synthetic
Active Components	CJC-1295Ipamorelin
Storage	Lyophilized room-temp; reconstituted 2–8°C up to 30 days
Form Factor	Two lyophilized powder vials (dual-vial stack)

Frequently Asked Questions

Sources & References

Every clinical claim on this page traces to a primary peer-reviewed source.

1Teichman SL, Neale A, Lawrence B, et al.. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism. 2006;91(3):799-805. doi:10.1210/jc.2005-1536 PMID:16352683
2Raun K, Hansen BS, Johansen NL, et al.. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-61. doi:10.1530/eje.0.1390552 PMID:9849822
3Alba M, Fintini D, Sagazio A, et al.. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology — Endocrinology and Metabolism. 2006;291(6):E1290-4. doi:10.1152/ajpendo.00201.2006 PMID:16822960